ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022
[Three cases of hemodiafiltration for the treatment of CAR-T related grade 3 - 4 cytokine release syndrome after ineffective treatment with IL-6 receptor inhibitors].
S Y Chen, W H Chen, X C Wan, X Du, C R Luo, X Q Li, X H Zhang
Open access · greenAbstract read
In one paragraphArticle in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 81% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors at 2 institutions in 1 country.
S Y ChenDepartment of Hematology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen 518035, China.
W H ChenDepartment of Hematology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen 518035, China.
X C WanProtein and Cell Drug Research Center, Institute of Biomedicine and Technology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
X DuDepartment of Hematology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen 518035, China.
C R LuoDepartment of Hematology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen 518035, China.
X Q LiDepartment of Hematology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen 518035, China.
X H ZhangDepartment of Hematology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen 518035, China.
Shenzhen Second People's Hospital · CNShenzhen Institutes of Advanced Technology · CN
Funding
Funding Shenzhen Science and Technology Innovation Committee JCJY2018022816 3509339Key-Area Research and Development Program of Guangdong Province 2019B020201014National Key R&D Program of China 2019YFA0906100Shenzhen Municipal Health Commission 201606021
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Cytokine Release SyndromeHemodiafiltrationImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffusePrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenHumansPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Interleukin-6Retrospective StudiesReceptors, Chimeric AntigenReceptors, Interleukin-6Chimeric antigen receptor T cellsCytokine release syndromeHemodiafiltrationIL-6 receptor inhibitor
Identifiers
PMID35968593
PMCPMC9800215
OpenAlexW4297580840
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390